{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:31:46Z","timestamp":1759159906858},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jcv.2014.06.023","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T00:31:15Z","timestamp":1404347475000},"page":"149-151","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patients eligible for treatment with simeprevir in a French center"],"prefix":"10.1016","volume":"61","author":[{"given":"Virginie","family":"Morel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Duverlie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Brochot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2014.06.023_bib0005","first-page":"737A","article-title":"Simeprevir (TMC435) with peg-interferon \u03b1-2a\/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial","volume":"58","author":"Forns","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2014.06.023_bib0010","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2014.06.023_bib0015","unstructured":"Huisman MT, Snoeys J, Monbaliu J, Martens M,. Sekar VJ, Raoof A, In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Poster 278 presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)."},{"key":"10.1016\/j.jcv.2014.06.023_bib0020","first-page":"756A","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment- na\u00efve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials","volume":"58","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2014.06.023_bib0025","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcv.2014.06.023_bib0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrd4050","article-title":"Novel therapies for hepatitis C \u2013 one pill fits all?","volume":"12","author":"Manns","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcv.2014.06.023_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","article-title":"Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a","volume":"99","author":"Palanisamy","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jcv.2014.06.023_bib0040","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/hep.1840210243","article-title":"Variability of hepatitis C virus","volume":"21","author":"Simmonds","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2014.06.023_bib0045","first-page":"e436","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"441","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665321400256X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665321400256X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T23:26:19Z","timestamp":1538436379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138665321400256X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S138665321400256X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2014.06.023","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients eligible for treatment with simeprevir in a French center","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2014.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}